Madero Magdalena, Sarnak Mark J, Wang Xuelei, Greene Tom, Beck Gerald J, Kusek John W, Collins Allan J, Levey Andrew S, Menon Vandana
Department of Medicine, Division of Nephrology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Am J Kidney Dis. 2009 May;53(5):796-803. doi: 10.1053/j.ajkd.2008.12.021. Epub 2009 Mar 20.
Hyperuricemia is prevalent in patients with chronic kidney disease (CKD); however, data are limited about the relationship of uric acid levels with long-term outcomes in this patient population.
Cohort study.
SETTING & PARTICIPANTS: The Modification of Diet in Renal Disease (MDRD) Study was a randomized controlled trial (N = 840) conducted from 1989 to 1993 to examine the effects of strict blood pressure control and dietary protein restriction on progression of stages 3 to 4 CKD. This analysis included 838 patients.
Uric acid level.
OUTCOMES & MEASUREMENTS: The study evaluated the association of baseline uric acid levels with all-cause mortality, cardiovascular disease (CVD) mortality, and kidney failure.
Mean age was 52 +/- 12 (SD) years, glomerular filtration rate was 33 +/- 12 mL/min/1.73 m(2), and uric acid level was 7.63 +/- 1.66 mg/dL. During a median follow-up of 10 years, 208 (25%) participants died of any cause, 127 (15%) died of CVD, and 553 (66%) reached kidney failure. In multivariate models, the highest tertile of uric acid was associated with increased risk of all-cause mortality (hazard ratio [HR], 1.57; 95% confidence interval [CI], 1.07 to 2.32), a trend toward CVD mortality (HR, 1.47; 95% CI, 0.90 to 2.39), and no association with kidney failure (HR, 1.20; 95% CI, 0.95 to 1.51) compared with the lowest tertile. In continuous analyses, a 1-mg/dL greater uric acid level was associated with 17% increased risk of all-cause mortality (HR, 1.17; 95% CI, 1.05 to 1.30) and 16% increased risk of CVD mortality (HR, 1.16; 95% CI, 1.01 to 1.33), but was not associated with kidney failure (HR, 1.02; 95% CI, 0.97 to 1.07).
Primary analyses were based on a single measurement of uric acid. Results are generalizable primarily to relatively young white patients with predominantly nondiabetic CKD.
In patients with stages 3 to 4 CKD, hyperuricemia appears to be an independent risk factor for all-cause and CVD mortality, but not kidney failure.
高尿酸血症在慢性肾脏病(CKD)患者中很常见;然而,关于该患者群体尿酸水平与长期预后之间关系的数据有限。
队列研究。
肾脏疾病饮食调整(MDRD)研究是一项于1989年至1993年进行的随机对照试验(N = 840),旨在研究严格血压控制和饮食蛋白质限制对3至4期CKD进展的影响。该分析纳入了838名患者。
尿酸水平。
该研究评估了基线尿酸水平与全因死亡率、心血管疾病(CVD)死亡率和肾衰竭之间的关联。
平均年龄为52±12(标准差)岁,肾小球滤过率为33±12 mL/min/1.73 m²,尿酸水平为7.63±1.66 mg/dL。在中位随访10年期间,208名(25%)参与者死于任何原因,127名(15%)死于CVD,553名(66%)进展至肾衰竭。在多变量模型中,与最低三分位数相比,尿酸最高三分位数与全因死亡率风险增加相关(风险比[HR],1.57;95%置信区间[CI],1.07至2.32),有CVD死亡率增加的趋势(HR,1.47;95% CI,0.90至2.39),与肾衰竭无关(HR,1.20;95% CI,0.95至1.51)。在连续分析中,尿酸水平每升高1 mg/dL与全因死亡率风险增加17%相关(HR,1.17;95% CI,1.05至1.30),与CVD死亡率风险增加16%相关(HR,1.16;95% CI,1.01至1.33),但与肾衰竭无关(HR,1.02;95% CI,0.97至1.07)。
主要分析基于单次尿酸测量。结果主要适用于相对年轻的以非糖尿病CKD为主的白人患者。
在3至4期CKD患者中,高尿酸血症似乎是全因和CVD死亡率的独立危险因素,但不是肾衰竭的独立危险因素。